newsfilter
← Latest News
PR Newswire·

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi shares fell over 80% on October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101.
  • The study aimed to assess safety, pharmacokinetics, & exploratory outcomes for idiopathic pulmonary fibrosis but failed to meet its goals.
  • Preliminary results showed that placebo-treated patients had lower percent predicted FVC compared to those treated with TTI-101.
  • Senior Partner James (Josh) Wilson is inviting investors who suffered significant losses to contact the firm directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • The firm has offices in New York, Pennsylvania, California, & Georgia & has recovered hundreds of millions of dollars for investors since 1995.
  • Additional case details are available at www.faruqilaw.com/TVRD.